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The intracellular angiotensin system buffers
deleterious effects of the extracellular paracrine system
Begoña Villar-Cheda1,2,5, Maria A Costa-Besada1,2,5, Rita Valenzuela1,2, Emma Perez-Costas3, Miguel Melendez-Ferro4 and
Jose L Labandeira-Garcia*,1,2
The ‘classical’ renin–angiotensin system (RAS) is a circulating system that controls blood pressure. Local/paracrine RAS,
identified in a variety of tissues, including the brain, is involved in different functions and diseases, and RAS blockers are
commonly used in clinical practice. A third type of RAS (intracellular/intracrine RAS) has been observed in some types of cells,
including neurons. However, its role is still unknown. The present results indicate that in brain cells the intracellular RAS
counteracts the intracellular superoxide/H2O2 and oxidative stress induced by the extracellular/paracrine angiotensin II acting on
plasma membrane receptors. Activation of nuclear receptors by intracellular or internalized angiotensin triggers a number of
mechanisms that protect the cell, such as an increase in the levels of protective angiotensin type 2 receptors, intracellular
angiotensin, PGC-1α and IGF-1/SIRT1. Interestingly, this protective mechanism is altered in isolated nuclei from brains of aged
animals. The present results indicate that at least in the brain, AT1 receptor blockers acting only on the extracellular or paracrine
RAS may offer better protection of cells.
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The ‘classical’ renin–angiotensin system (RAS) is a circulating
humoral system that controls blood pressure. The actions of
angiotensin II (AII), themost important effector peptide in RAS,
are mediated by two main cell receptors: AII type 1 and 2 (AT1
and AT2). AT1 receptors mediate major effects of the system,
and it is generally considered that protective AT2 receptors
antagonize the pro-oxidative effects of AT1 receptors.1 More
recently, local or tissue RAS has been identified in a variety of
tissues, including the central nervous system.2 It is now known
that the local brain RAS is involved in different brain functions,
and also appears to be altered in some disorders.3,4 In
previous studies, we have demonstrated the presence of a
local RAS in the substantia nigra pars compacta (SNc) and
striatum of rodents and primates, including humans.5–7 This
local RAS modulates dopamine release8,9 possibly via mutual
regulation between dopamine and angiotensin receptors.10–12
However, dysregulation of these interactions exacerbates
neuroinflammation, oxidative stress and dopaminergic neuron
death.13,14 In addition, immunohistochemical studies have
revealed an apparent intracellular localization of several RAS
components in different types of cells, including dopaminergic
neurons and glial cells of mammals, including non-human
primates and human.5,15,16 However, the role of the intracel-
lular RAS, and particularly the nuclear components of the
RAS, is still unknown. In the present study we investigated the
presence and possible role of major RAS components in brain
cell nuclei. In particular, we investigated the possible effects of
nuclear angiotensin receptors in the transcription of other
components of the intracellular RAS and of several proteins
that act as major regulators of the mitochondrial function. Our
experiments were carried out in rats, knockout (KO) and
transgenic mice, as well as in the MES 23.5 dopaminergic
neuron cell line. A major difficulty in elucidating the role of
intracellular RAS is to separate the responses induced by
intracellular AII through intracellular or nuclear receptors from
those induced by extracellular AII through activation of cell
surface receptors. To overcome this technical difficulty, we
investigated the effect of AII both in cells and in isolated nuclei.
Our results show that nuclear angiotensin receptors control
key events for nuclear–mitochondrial interaction and neuronal
survival.
Results
Localization of AT1 and AT2 receptors in the nucleus of
dopaminergic neurons. Our previous immunohistochem-
ical and laser confocal microscopy studies have revealed
immunolabeling for AT1, AT2 receptors and angiotensinogen
in the nuclei of SNc dopaminergic neurons and MES 23.5
dopaminergic neuron cell line.5 In the MES 23.5 dopaminer-
gic neuron cell line, labeling for AT1 and AT2 receptors also
colocalized with the nuclear marker Hoechst 33342
(Figures 1a and b). Samples for electron microscopy were
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obtained from the densely packed dopaminergic cell clusters
of the rat SNc, where immunoelectron microscopy confirmed
the labeling for both AT1 and AT2 receptors in the nuclear
membranes of dopaminergic neurons (Figures 1c and d).
Nuclei were isolated from the rat nigral region in the ventral
mesencephalon (Figures 1e and f), and the quality of the
isolation was demonstrated by the absence of markers of the
cytosol fraction such as α-tubulin, and membrane markers
Figure 1 Nuclear AT1, AT2 receptors and NOX4 in nuclei from MES 23.5 dopaminergic neurons and rat nigral region. (a and b) MES 23.5 dopaminergic neurons showing
triple immunolabeling for the dopaminergic marker (TH), the nuclear marker (Hoechst), and AT1 (a) or AT2 (b) receptors. (c and d) Electron microscopy of AT1 and AT2 labeling
(white arrows) in nuclei and nuclear membranes (between black arrowheads) of rat dopaminergic neurons. (e and f) Nuclei isolated from the rat nigral region in the ventral
mesencephalon; the integrity of nuclei was confirmed by microscopic examination with phase contrast (e) and Hoechst staining (f); areas boxed in (e and f) are magnified in
(e1 and f1), respectively. (g) WB of whole homogenate (WH) and isolated nuclei (N) from the nigral region showing the expression of AT1 and AT2 receptors, Nox4, as well as
different compartment markers used to assess the purity of the nuclei isolation (HDAC2 as a nuclear marker; tubulin as a cytosol marker; and Na+/K+-ATPase as plasma
membrane marker). Note the higher expression of AT1 and lower expression of AT2 in the nucleus compared to receptors in WH (g and h). Data are mean±S.E.M. *Po0.05
compared to WH. Student’s t-test (n= 3–4). Scale bars: 150 μm (a and b), 0.5 μm (c and d) and 50 μm (e and f)
Nuclear angiotensin receptors
B Villar-Cheda et al
2
Cell Death and Disease
such as Na+/K+-ATPase. In addition, the presence of the
nuclear fraction was confirmed with the use of the nuclear
marker histone deacetylase 2 (HDAC2; Figure 1g). The two
main angiotensin receptor types (i.e., AT1 and AT2) were
observed in the nuclear fraction. There was a clear difference
in the abundance of each receptor subtype; the AT2 receptor
appeared less abundant in nuclear than in total cell homo-
genates, while the opposite occurred for the AT1 receptor
(Figures 1g and h). We also observed the presence of Nox4,
which is a major cell source of intracellular ROS in the nuclear
fraction (Figures 1g and h).
Effects of AII on nuclear RAS components. Twenty-four
hours after transient transfection of the MES 23.5 dopami-
nergic neuron cell line, AT1 and AT2 receptors labeled with
fluorescent proteins (enhanced green fluorescent protein,
Figure 2 Presence of fluorescence-tagged angiotensin receptors and fluorescent AII in nuclei. Colocalization (c, f and i) of the fluorescent nuclear marker Hoechst (a, d and
g) with AT1-EGFP (b), AT2-YFP (e) or AII-Rhod (h). WB analysis of GFP-/YFP-tagged protein in MES 23.5 transfected (+) and not transfected (− ) cells showing the specificity of
the common anti-GFP/YFP antibody (j). Treatment of MES 23.5 dopaminergic neuron cell line with AII increased nuclear AT1-EGFP receptor protein but not nuclear AT2-YFP
receptor protein relative to nuclei of control cells (k and l). Data are mean± S.E.M. *Po0.05 compared to control. Student’s t-test (n= 3–4). AT2-YFP, AT2 tagged to YFP; AT1-
EGFP, AT1 tagged to EGFP; AII-Rhod, rhodamine-fluorescent AII. Scale bar: 20 μm (a–i)
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EGFP; yellow fluorescent protein, YFP) were located both at
the plasma membrane and intracellularly, and they coloca-
lized with the nuclear marker Hoechst 33342 (Figures 2a–f).
In a second series of experiments, cultures of the MES 23.5
dopaminergic neuron cell line were treated with rhodamine-
conjugated AII to investigate the localization of AII within the
nucleus. The fluorescent AII was internalized and colocalized
with the nuclear marker Hoechst 33342, which was evident
after 30 min, and persisted for 24 h after treatment
(Figures 2g–i).
Interestingly, treatment of the MES 23.5 dopaminergic
neuron cell line with 100 nM AII increased nuclear AT1-
EGFP fluorescence in these cells relative to nuclei from control
cells. However, the same treatment did not induce any
significant increase in the levels of nuclear AT2-YFP fluores-
cence relative to control cells. These effects were confirmed
by western blot (WB) in samples from isolated nuclei
(Figures 2j–l).
RT-PCR analysis of brain-isolated nuclei revealed that
treatment with 100 nM AII induces a significant increase in
angiotensinogen and AT2 receptor mRNA expression
(Figures 3a and b), as well as an increase in the expression
of mRNA for renin and prorenin/renin receptors (PRRs;
Figures 3c and d). In contrast, the levels of AT1 receptor
mRNA did not change significantly (Figure 3e). The increases
in mRNA expression induced by All for the abovementioned
RAS components were inhibited by simultaneous treatment
with the AT1 receptor antagonist losartan, which indicates that
these effects are mediated via nuclear AT1 receptors. This
was confirmed by treatment of isolated nuclei from AT1 and
AT2 KO mice. AII induced the abovementioned effects in AT2
KO, but not in AT1 KO mice (Figures 3f and g). The effects of
AII on brain-isolated nuclei were confirmed in nuclei from the
MES 23.5 dopaminergic neuron cell line, in which AII
treatment also increased mRNA expression for AT2 receptors
and angiotensinogen, but not mRNA expression for AT1
receptors (Figure 3h).
Effects of AII on the transcription of PGC-1α, IGF-1 and
SIRT1 in isolated nuclei. Treatment of isolated nuclei with
100 nM AII led to an ~60% increase in mRNA expression for
PGC-1α and a twofold increase in mRNA expression for
IGF-1. These increases were inhibited by the simultaneous
treatment with the AT1 receptor blocker losartan, suggesting
that AII acts via nuclear AT1 receptors (Figures 4a and c).
When nuclei isolated from KO AT1 and KO AT2 mice
were treated with All the effect was observed in nuclei from
KO AT2 mice, but was absent in nuclei from KO AT1 mice
(Figures 4b–d).
Isolated nuclei were also treated with AII to assess its
effects onmRNA expression for SIRT1. However, the increase
in SIRT1 mRNA induced by All was not significant (Figure 4e).
To further investigate a possible interaction between SIRT1
and the nuclear RAS we investigated the expression of AT1
and AT2 receptors in nuclei isolated from transgenic mice
overexpressing SIRT1. Interestingly, these mice showed a
significant decrease in the levels of nuclear AT1 receptors, but
a significant increase in the levels of nuclear AT2 receptors
(Figure 4f). The results observed in nuclei isolated from the
brain nigral region were also observed in nuclei isolated from
the MES 23.5 dopaminergic neuron cell line, where AII
treatment also produced an increased mRNA expression for
PGC-1α and IGF-1, but a nonsignificant increase in mRNA
expression for SIRT1 (Figure 4g).
Effects of AII on superoxide/H2O2, calcium and nitric
oxide levels in isolated nuclei. Treatment of brain-isolated
nuclei with AII induced a significant increase in the levels of
nuclear superoxide/H2O2, which was inhibited by simulta-
neous treatment with the AT1 receptor blocker losartan, but
not by the simultaneous treatment with the AT2 receptor
blocker PD123,319 (Figure 5a). The increase in superoxide/
H2O2 induced by All was also inhibited by the simultaneous
treatment with the antioxidant N-acetyl-cysteine (NAC) or the
simultaneous treatment with the Nox4 inhibitor (diphenyle-
neiodonium, DPI; Figure 5b). Altogether these results
suggest that at the nuclear level, AII activates the AT1/Nox4
axis to induce the release of superoxide/H2O2. The role of
AT1 and AT2 receptors in AII-induced nuclear superoxide/
H2O2 release was confirmed in isolated nuclei from AT1 and
AT2 KO mice (Figure 5c). Levels of superoxide/H2O2 were
significantly lower in nuclei from KO AT1 mice than from wild-
type (WT) mice. Nuclei from KO AT2 mice showed
significantly higher levels of superoxide/H2O2 than nuclei
from WT mice. Treatment of nuclei from KO AT1 mice with AII
induced a significant additional decrease in the levels of
nuclear superoxide/H2O2 (possibly as a result of the effect of
AII on nuclear AT2 receptors). Treatment of isolated nuclei
from KO AT2 mice with AII induced an additional increase in
the levels of nuclear superoxide/H2O2. Altogether these
results reveal an opposite effect of AT1 (marked increase),
and AT2 (slight decrease) nuclear receptors on the levels of
nuclear superoxide/H2O2.
The observations in brain nuclei were confirmed in nuclei
isolated from the MES 23.5 dopaminergic neuron cell line, in
which AII treatment also induced a significant increase in the
levels of nuclear superoxide/H2O2. This effect was inhibited by
the simultaneous treatment with the AT1 receptor blocker
losartan or the Nox4 inhibitor DPI, but not by the simultaneous
treatment with the AT2 receptor antagonist PD123,319
(Figure 5d).
The AII-induced increase in AT2 receptor or PGC-1α
mRNAs (Figures 3 and 4) was not blocked by the simulta-
neous treatment with the antioxidant NAC or the Nox inhibitor
DPI, at least in the present experimental conditions. This
suggests that the AII-induced increase in nuclear levels of
superoxide/H2O2 does not mediate the abovementioned
effects on transcription (Figures 5e and f).
Treatment of isolated nuclei with AII led to increased levels
of nuclear calcium, which were inhibited by treatment with the
AT1 receptor blocker losartan, indicating that the effect is
mediated by AT1 receptors (Figure 6a). Interestingly, the
simultaneous treatment of isolated nuclei with the IP3 receptor
inhibitor 2-aminoethyl diphenylborinate (2-APB) inhibited the
AII-induced increase in AT2 and PGC-1α mRNAs, suggesting
that these effects are mediated by Ca2+ via nuclear
IP3·receptors (Figures 6b and c).
Treatment of isolated nuclei with AII and the AT1 blocker
losartan induced a significant increase in nitric oxide (NO)
levels, which was inhibited by simultaneous treatment with the
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AT2 receptor antagonist PD123,319 (Figure 6d). This indi-
cates that nuclear AT2 receptors mediate the AII-induced
production of nuclear NO. The AII-induced increase in nuclear
NO was also inhibited by simultaneous treatment with the NO
synthase (NOS) inhibitor, N-nitro-L-arginine methyl ester (L-
NAME), which indicates that the nuclear NO synthase
involved in this process.
Effects of AII on isolated nuclei from aged rats. Nuclei
isolated from brains of aged rats showed a significant
decrease in the levels of both AT1 and AT2 receptors
(Figure 7a). Interestingly, treatment of these nuclei with
100 nM AII did not induce any significant increase in mRNA
expression for IGF-1, PGC-1α or AT2 receptors (Figure 7b).
Similarly, the AII-induced increase in the levels of superoxide/
Figure 3 Effect of angiotensin (AII) on transcription of different RAS components. Treatment of rat-isolated nuclei with AII induced an increase in the expression of mRNA for
AT2 (a), angiotensinogen (ANG; b), renin (c) and PRRs (d), which was inhibited by simultaneous treatment with the AT1 receptor antagonist losartan (los), indicating that these
effects are mediated via nuclear AT1 receptors. In contrast, the levels of AT1 receptor mRNA did not change significantly after AII administration (e). The role of AT1 receptors in
these effects was confirmed in isolated nuclei from AT1 and AT2 KO mice treated with AII (f and g). The effects of AII on brain-isolated nuclei were also observed in nuclei from the
MES 23.5 dopaminergic neuron cell line (h). Data are mean±S.E.M. *Po0.05 compared to control, #Po0.05 compared to the group treated with AII. One-way analysis of
variance and Holm–Sidak post hoc test (a–e) and Student’s t-test (f–h) (n= 4–8)
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H2O2 was not statistically significant in these nuclei
(Figure 7c). As observed in nuclei from young KO AT1 mice
(Figure 5c), the levels of nuclear superoxide/H2O2 were signi-
ficantly lower in aged KO AT1 mice than in WT aged mice.
Treatment with AII did not induce any significant increase in
the levels of superoxide/H2O2 in nuclei from aged KO AT1 mice,
as previously observed in young KO AT1 mice (Figure 7d).
Discussion
We report here the presence of AT1 and AT2 receptors as well
as Nox4 in isolated nuclei from brain cells. AT1 receptors were
more abundantly expressed in isolated nuclei than in the total
cell homogenate, while the opposite occurred for AT2
receptors. Interestingly, we recently observed the opposite in
isolated mitochondria, where AT2 are much more abundant
than AT1 receptors.17 Treatment of the MES 23.5 dopaminer-
gic neuron cell line with AII induced an increase in the
expression of nuclear AII and AT1 receptors. In contrast,
treatment of isolated nuclei with AII induced, via AT1
activation, an increase in AT2 mRNA but not AT1 mRNA
transcription. The presence of AT1 receptors in the nucleus
has been observed in several types of peripheral cells,
although the function of nuclear angiotensin receptors was
Figure 4 Effect of angiotensin (AII) on transcription of PGC-1α, IGF-1 and SIRT1. Treatment of isolated nuclei with AII induced an increase in the expression of mRNA for
PGC-1α (a) and IGF-1 (c), which was inhibited by the simultaneous treatment with the AT1 receptor antagonist losartan (los), indicating that these increases are mediated via
nuclear AT1 receptors. This was confirmed by treatment of isolated nuclei from AT1 and AT2 KO mice with AII (b and d). The expression of SIRT1 mRNA did not change
significantly after treatment of isolated nuclei with AII (e). However, nuclei isolated from mice overexpressing SIRT1 (SIRT1-TG) showed a decrease in the expression of nuclear
AT1, and an increase in the levels of AT2 receptors (f). The effects of AII on brain-isolated nuclei were also observed in nuclei from the MES 23.5 dopaminergic neuron cell line (g).
Data are mean± S.E.M. *Po0.05 compared to control or WT (f), #Po0.05 compared to the group treated with AII. One-way analysis of variance and Holm–Sidak post hoc test
(a, c and e), and Student’s t-test (b, d, f and g) (n= 4–8)
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not clarified.18,19 In renal cells, a rapid internalization of
the AII–AT1 receptor complex, via receptor-mediated endo-
cytosis, has been reported.20–22 AT2 receptors lack a
canonical nuclear localization sequence as AT1 receptors
do, and generally they are not internalized following ligand
activation in vascular or renal cells.23,24 It has been suggested
that the intracellular RAS may serve to amplify events that are
initiated in the plasma membrane, leading to signal amplifica-
tion in successive steps with reutilization and minimal
waste.18,25 Quite the opposite, the results of the present study
suggest that the intracellular, and particularly the nuclear RAS,
may counteract and modulate the deleterious effects of the
membrane AII/AT1 activation (Figure 8). Extracellular (i.e.,
paracrine) AII induces activation of the membrane AT1–Nox2
axis, with the generation of intracellular superoxide/H2O2 and
oxidative stress, but also induces the internalization of the AII–
AT1 receptor complex to the nucleus. We observed that
activation of nuclear AT1 receptors by intracellular AII triggers
a number of mechanisms that may protect cells against
oxidative stress. These mechanisms include an increase in
the levels of AT2 receptors and intracellular angiotensin, as
well as of PGC-1α and IGF-1. Interestingly, this protective
mechanism is altered in isolated nuclei from brains of aged
animals.
Figure 5 Effect of angiotensin (AII) on nuclear superoxide/H2O2 production, AT2 and PGC-1α mRNA expression. Treatment of isolated nuclei with AII increased the levels of
nuclear superoxide/H2O2 (i.e., DHE fluorescence; a–d), which were inhibited by the simultaneous treatment with the AT1 receptor antagonist losartan (a; los), the antioxidant NAC
and the Nox inhibitor DPI (b), but not by the AT2 receptor antagonist PD123,319 (PD) (a). Involvement of AT1 in these effects was confirmed by treatment of nuclei from AT1 and
AT2 KO mice with AII, which also revealed an opposite effect of nuclear AT1 (increase) and AT2 (decrease) receptors on the levels of nuclear superoxide/H2O2 (c). The effects of
AII on brain nuclei were also observed in nuclei from the MES 23.5 dopaminergic neuron cell line (d). However, the effects of AII on AT2 (e) and PGC-1α (f) mRNA expression
were not inhibited by the antioxidant NAC or the Nox inhibitor DPI. Data are mean± S.E.M. *Po0.05 compared to control or WT (c), &compared to KO AT1, #Po0.05 compared
to group treated with AII (a, b and d) or KO AT2 (c). One-way analysis of variance and Holm–Sidak post hoc test (n= 4–10)
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Effects of nuclear AII/AT1 activation on nuclear RAS
components. Activation of nuclear AT1 receptors by AII
induces an increase in the expression of AT2 receptor mRNA.
This may lead to an increase in the levels of protective AT2
receptors that traffic to different cell structures such as
mitochondria and membrane. A compensatory increase in
the opposite or protective arm of the RAS (i.e., AII/AT2)
has been observed in different studies after increasing the
activity of the membrane AII/AT1/Nox2/superoxide axis.26–28
Consistent with this, we have recently shown that AT2
receptors are particularly abundant in mitochondria and that
mitochondrial AT2 receptors, via NO, downregulate mito-
chondrial respiration to counteract oxidative stress in
neurons.17 In the present study, we observed that nuclear
AT2 receptor activation increases the levels of nuclear NO,
and our observations in AT1 and AT2 KO mice suggest that
nuclear AT2 receptors modulate the effects of nuclear AT1
receptors. In addition to an increase in AT2 mRNA expres-
sion, activation of AT1 nuclear receptors by AII induced an
increase in the expression of mRNA for angiotensinogen,
renin and renin–prorenin receptors, which indicates that an
increase in the synthesis of intracellular angiotensin may
further act on intracellular AT2 receptors to counteract
oxidative damage.
Effects of nuclear AII/AT1 activation on transcription of
PGC-1α. Activation of nuclear AT1 receptors also induced an
increase in mRNA expression for PGC-1α. Members of the
PGC-1 family have emerged as master transcriptional
regulators of the mitochondrial function that improve or
rescue mitochondrial dysfunction.29–32 In dopaminergic neu-
rons, PGC-1α has been shown to be essential for survival,
possibly through the maintenance of mitochondrial function,
as conditional PGC-1α KO mice show a significant loss of this
type of neurons,33,34 while overexpression of PGC-1α protects
dopaminergic neurons.33–37 The present results show that
activation of nuclear AT1 receptors by AII induces an increase
in the expression of PGC-1α that may counteract the pro-
oxidative effects of activation of the surface membrane AT1
receptor. Nuclear AT2 receptors modulate this process by
counteracting the effects of nuclear AT1 receptors.
Effects of nuclear AII/AT1 activation on transcription of
IGF-1 and SIRT1. We also investigated the effect of
activation of nuclear AT1 receptors on two additional factors
(i.e., IGF-1 and SIRT1) that have been shown to modulate
mitochondrial function and to interact with the RAS in studies
performed at tissue and cellular levels.38,39 IGF-1 has been
found to increase survival of dopaminergic neurons,40–42 and
Figure 6 Effect of angiotensin (AII) on nuclear calcium and NO levels. Treatment of rat-isolated nuclei with AII induced a significant increase in nuclear calcium (a), NO levels
(d), which were inhibited by the simultaneous treatment with the AT1 receptor antagonist losartan (los) and the AT2 receptor antagonist PD123,319 (PD), respectively. Treatment
of isolated nuclei with AII also induced an increase in the expression of mRNA for AT2 (b) and PGC-1α (c), which was inhibited by the simultaneous treatment with the IP3
receptor blocker 2-APB, suggesting that Ca2+ signaling is involved in these transcriptional changes. The AII-induced increase in nuclear levels of NO was inhibited by the NOS
inhibitor L-NAME (d). Data are mean± S.E.M. *Po0.05 compared to control, #Po0.05 compared to the group treated with AII, &compared to the group treated with AII+los. One-
way analysis of variance and Holm–Sidak post hoc test (n= 4–8)
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activation of nuclear AT1 receptors increases the expression
of IGF-1 mRNA. The cytoprotective effects of IGF-1 have
been related to mitochondrial protection, leading to a
reduction of free radical production, oxidative damage and
apoptosis.43,44 IGF-1 has been suggested to inhibit cell death
triggered by oxidative stressors via increasing expression of
SIRT1.45
SIRT1 is present in the nucleus and cytoplasm. It
deacetylates several proteins involved in cell survival,
metabolism and stress response, and stimulates resistance
to oxidative stress in several types of cells.46 Several studies
lead to the conclusion that SIRT1 exerts its control over
mitochondrial function mainly by regulating PGC-1α
activity.30,31,47 In a recent study, we observed that AII induced
an increase in SIRT1 expression in dopaminergic neurons and
microglia.38 However, the activation of AT1 nuclear receptors
in isolated nuclei did not induce any significant increase in
SIRT1 mRNA. This suggests that certain components located
in the cytoplasm are involved in the increase in expression of
SIRT1 induced by membrane AII/AT1 activation. The above-
mentioned increase in expression of IGF-1 may be a possible
mechanism, as it has been observed that IGF-1 induced an
increase in SIRT1 expression in cardiomyocytes.45 The
involvement of nuclear angiotensin receptors in the regulation
of SIRT1 levels is suggested by our observations in isolated
nuclei from transgenic mice overexpressing SIRT1. Over-
expression of SIRT1 led to a decrease in expression of nuclear
AT1 receptors and an increase in expression of AT2 nuclear
receptors, which suggests a possible feedback regulation of
the abovementioned mechanism. This is also consistent with
observations showing that overexpression of SIRT1 in muscle
cells downregulates PGC-1α.48 In summary, activation of
nuclear AT1 receptors by AII may trigger a compensatory
mechanism by increasing both PGC-1α and SIRT1 via IGF-1.
Effects of nuclear AII/AT1 activation on nuclear calcium
and superoxide/H2O2 levels. We have observed that
activation of nuclear AT1 receptors induces an increase in
nuclear superoxide/H2O2 as well as in Ca
2+ levels, which
have been shown to activate signaling pathways that
influence gene expression in different types of cells. Nuclear
Ca2+ signaling is an important regulator of gene
transcription,49 and IP3 receptors are involved in Ca2+
signaling.50 Calcium has been shown to directly bind
Figure 7 Nuclear AT1 and AT2 receptors in aged rats and mice. Nuclei isolated from brains of aged rats showed a significant decrease in the levels of both AT1 and AT2
receptors (a). Treatment of nuclei with AII did not induce any significant increase in AT2, angiotensinogen (ANG) and PGC-1α mRNA expression (b), or in the levels of nuclear
superoxide/H2O2 (c). Levels of nuclear superoxide/H2O2 were significantly lower in aged KO AT1 mice than in WTaged mice, and treatment with AII did not induce any significant
increase in superoxide/H2O2 in nuclei from aged KO AT1 mice (d). Data are mean± S.E.M. *Po0.05 compared to the corresponding control, #Po0.05 compared to aged WTor
aged WT treated with AII. One-way analysis of variance and Holm–Sidak post hoc test (b and d) and Student’s t-test (a and c) (n= 3–8)
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transcription factors like DREAM,51 or activate the nuclear
CaM kinase pathways that regulate gene expression.52 In the
present study inhibition of nuclear IP3 receptors inhibited the
AII-induced increase in AT2 and PGC-1α mRNAs, which
suggests that Ca2+ signaling is involved in these transcrip-
tional changes.
It has also been suggested that Nox4 regulates gene
expression in a manner dependent on regulatory DNA
sequence Maf-recognition element, constituting part of the
antioxidant response.53 Unexpectedly, the simultaneous
treatment of isolated nuclei with AII and the antioxidant NAC
or the Nox inhibitor DPI did not inhibit the increase in
expression of AT2 or PGC-1α, at least in the conditions used
in the present experiments. Nox-derived superoxide/H2O2
may be involved in the transcription of other factors of
the antioxidant response, possibly related to hormetic
adaptations to oxidative stress similar to those described in
mitochondria.54
Role of nuclear RAS in aging. Aging is the highest risk
factor for neurodegenerative diseases, particularly PD. In
previous studies we observed that aged rats show an
increase in the activity of the AII/AT1/Nox2 axis,10,55,56 which
leads to increased levels of oxidative stress and neuroin-
flammatory markers in the nigral region. Aged animals
showed an important increase in the expression of AT1
receptors, as well as a marked decrease in the expression of
AT2 receptors in brain homogenates (particularly nigral and
striatal homogenates). However, aged rats also showed a
decrease in the levels of IGF-1 and SIRT1 in the nigral
region.39,38 The present findings explain these apparent
paradoxical differences between young and aged rats. Nuclei
from aged rats showed a significant decrease in the levels of
both nuclear AT1 and AT2 receptors, and treatment of aged
nuclei with AII did not induce any significant increase in the
levels of nuclear superoxide/H2O2, or in the expression of
AT2, angiotensinogen, IGF-1 or PGC-1αmRNA. This suggest
that the above-described nuclear compensatory response
triggered by nuclear AT1 receptors is impaired in aged cells,
which leads to the decrease in AT2, IGF-1 and SIRT1
expression observed in aged animals. In a recent study, we
observed that the expression AT2 receptors is decreased in
mitochondria of aged rats, which may affect mitochondrial
protection against oxidative stress.17 Deterioration of mito-
chondrial function and biogenesis has been postulated as a
central landmark of aging, which has been related to a
decline in PGC/mitochondrial function together with a
decreased expression of PGC-regulated oxidative defense
mechanisms.47
Conclusions
The present results, and the results of our recent study,17
suggest that the intracellular RASmay buffer the pro-oxidative
effects of activation of membrane AT1 receptors by extra-
cellular (paracrine) AII. Internalization of the AII–AT1 complex
to the nucleus, and activation of nuclear AT1 receptors by
intracellular AII triggers a number of mechanisms that may
protect cells against oxidative stress. Interestingly, this
protective mechanism is altered in nuclei from brains of aged
animals. Previous studies in non-neural cells have suggested
that the intracellular RAS may serve to amplify events that are
initiated in the plasma membrane. On this basis, it was
assumed that intracellular AII contributes to disease progres-
sion, and that AT1 receptor blockers that are effective against
extracellular and intracellular receptors, or the recent renin
inhibitors that act at extra- and intracellular levels may bemore
effective to combat the effects of RAS overactivity on different
tissues. Interestingly, it has been observed that some AT1
blockers such as candesartan act mostly on surface receptors,
and other AT1 blockers such as losartan act both on surface
and intracellular receptors.57 The present results indicate that
at least in the brain, AT1 receptor blockers acting only on the
extracellular or paracrine RAS may offer better protection
of cells.
Figure 8 Model of the role that nuclear AT1 and AT2 receptors have in
modulating the pro-oxidative effects of activation of membrane AT1 receptors by
extracellular (i.e., paracrine) AII. Extracellular AII induces activation of the membrane
AT1/Nox2 axis, with the generation of intracellular superoxide/H2O2 and oxidative
stress (red arrows), but also induces the internalization of the AII–AT1 receptor
complex to the nucleus (green arrows). Activation of nuclear AT1 receptors induces
an increase in nuclear NOX4/superoxide/H2O2 and IP3/Ca
2+ levels, which are known
to regulate gene expression, triggering a number of mechanisms that may protect
cells against oxidative stress (green arrows). These protective mechanisms include
the following: (i) an increase in the expression of AT2 receptor mRNA, which leads to
an increase in the levels of protective AT2 receptors that traffic to different cell
structures such as mitochondria and membrane and induces a compensatory
increase in the RAS protective arm (i.e., AII/AT2); (ii) an increase in angiotensinogen,
renin and PRR mRNA, which leads to an increase in the synthesis of intracellular AII
to act on intracellular AT2 receptors; (iii) an increase in mRNA expression for PGC-1α
and IGF-1, which, interacting with SIRT1, have been related to mitochondrial
protection and reduction of free radical production and oxidative damage. Nuclear
AT2 receptors modulate this process (blue arrows) and counteract the effects of
nuclear AT1 receptors by increasing nuclear levels of NO, which was particularly
shown using isolated nuclei from AT1 and AT2 KO mice. IGF-1, insulin-like growth
factor 1; IP3R, inositol 1,4,5-trisphosphate receptor; PGC-1α, peroxisome
proliferator-activated receptor gamma coactivator 1-alpha; ROS, reactive oxygen
species; SIRT1, sirtuin 1
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Materials and Methods
Experimental design. In a first series of experiments brain sections from the
substantia nigra of adult male Sprague–Dawley rats, and cultures of the MES 23.5
dopaminergic cell line were used to investigate the presence of AII receptors in the
nuclei of dopaminergic cells, using immunofluorescence and electron microscopy.
All experiments were carried out in accordance with the Directives 2010/63/EU and
86/609/CEE, and were approved by the corresponding ethics committee at the
University of Santiago de Compostela. Animals were housed at constant room
temperature (RT; 21–22 °C) and 12 h light/dark cycle. All surgeries were performed
under ketamine/xylazine anesthesia. In a second series of experiments, isolated
nuclei from rat nigral region were used to confirm the expression of AII receptors
using WB assay. In addition, dopaminergic cells were transfected with fluorescent-
tagged AT1 and AT2 receptors, or treated with fluorescent AII to investigate the
colocalization of fluorescence with nuclear markers, and to confirm the results
observed with immunolabeling.
For functional studies, we used nuclei isolated from the brain of young
(8–10 weeks old) and aged (18–20 months old) Sprague–Dawley rats, as well as
young (8–10 weeks old) and aged (18–20 months old) mice, and the MES 23.5
dopaminergic neuron cell line (generously provided by Dr. Wei-Dong Le). The
following groups of mice were used: (1) male WT C57BL-6 mice (Charles River,
L’Arbresle, France), and young and aged homozygous C57BL-6 mice deficient for
AT1a (the major mouse AT1 isoform, and the closest murine homolog to the single
human AT1; Jackson Laboratory, Bar Harbor, ME, USA); and (2) young and aged
homozygous C57BL-6 mice deficient for AT2 receptors (gift of Dr. Daniel Henrion). A
third group of C57BL-6 mice comprised young and aged transgenic mice in which
SIRT1 is moderately overexpressed under its own promoter, thereby following the
physiological pattern of expression,58 and the corresponding WT controls. Nuclei
were incubated with AII (100 nM, Sigma, St. Louis, MO, USA) and different blockers
to assess the effect of activation of AT1 and AT2 nuclear receptors on mRNA
transcription, nuclear superoxide/H2O2 levels, NO or calcium levels. The blockers
used included the AT1 antagonist losartan (3 μM, Sigma), the AT2 antagonist
PD123,319 (1 μM, Sigma), the Nox inhibitor DPI (5 μM Sigma), the antioxidant NAC
(0.5 mM, Sigma) and the inhibitor of inositol 1,4,5-trisphosphate receptor 2-APB
(50 μM, Sigma).
Inmunofluorescent labeling. Double immunofluorescence labeling was
performed to identify the cells that expressed angiotensinogen/angiotensin, AT1R,
AT2R and PRR in the rat SNc, as described in our previous studies.5,7
Angiotensinogen/angiotensin, AT1R, AT2R and PRR antibodies were combined with
antibodies against tyrosine hydroxylase (TH; as a marker of dopaminergic neurons),
glial fibrillary acid protein (a marker of astrocytes) and OX42 (a marker of both
resting and reactive microglia (not shown; see ref. 5 for details).
The MES 23.5 dopaminergic neuron cell line was cultured in DMEM/F12
containing Sato’s component growth medium supplemented with 2% FBS, 100 U/ml
penicillin and 100 μg/ml streptomycin, at 37 °C in a humidified CO2 incubator (5%
CO2, 95% air). MES 23.5 cells were plated at a density of 0.4 × 10
6 onto 35 mm
plastic dishes with glass coverslips previously coated with poly-L-lysine (Sigma;
10 mg/ml), fixed in 4% paraformaldehyde in Dulbecco’s phosphate-buffered saline
(DPBS; pH 7.4) for 20 min, and incubated overnight with the anti-AT1 (sc-31181;
1:50) or anti-AT2 (sc-9040; 1:200) polyclonal antibodies (both from Santa Cruz
Biotechnologies, Dallas, TX, USA). After rinsing with DPBS, cells were incubated for
150 min with the Alexa-conjugated secondary antibody (Molecular Probes, Eugene,
OR, USA) and then stained with Hoechst (10 μg/ml; Sigma). Labeling was visualized
using a confocal laser-scanning microscope (AOBS-SP5X; Leica Microsystems,
Heidelberg GmbH, Mannheim, Germany). Confocal images were obtained by
sequential scan using three different laser lines to avoid simultaneous excitation and
possible overlap. Colocalization analysis was subsequently performed with the
captured images to detect double-labeled cells. Analysis of the photographs at central
cell levels revealed the location of labeling (peripheral ring suggesting membrane,
cytoplasm or in the nucleus). In negative controls, in which the primary antibody was
omitted, no immunostaining was observed.
Inmunoelectron microscopy. Adult male Sprague–Dawley rats were
deeply anesthetized with a mixture of ketamine/xylazine and perfused with saline
(0.09% NaCl) followed by a solution of 4% paraformaldehyde and 0.1%
glutaraldehyde in 0.1 M phosphate buffer (PB, pH 7.4) After perfusion, brains
were quickly removed from the skull, immersed in the same fixative solution
overnight at 4 °C and rinsed thoroughly in PB. Free-floating 40 μm coronal sections
were obtained on a vibratome and stored in PB until use. Sections containing the
substantia nigra were transferred to citrate buffer, pH 6.0 (Vector Laboratories,
Burlingame, CA, USA) at RT for 5 min and then to citrate buffer at 80 °C for 30 min.
Sections were rinsed consecutively in citrate buffer and phosphate-buffered saline
(PBS; pH 7.4) at RT before pre-treatment with 1% sodium borohydride in PBS for
15 min. Sections were rinsed several times in PBS, then transferred to a solution of
5% hydrogen peroxide in PBS for 30 min and rinsed several times in PBS. Sections
were pre-incubated in 10% normal serum containing 0.01% Triton X-100 in PBS for
1 h and then incubated for 72 h at 4 °C with the appropriate primary antibody:
mouse monoclonal anti-TH (Sigma; 1:10000); AT1 goat polyclonal diluted 1:100; or
AT2 rabbit polyclonal diluted 1:200 (Santa Cruz Biotechnologies catalog number sc-
31181 and sc-9040, respectively). Sections were rinsed thoroughly in PBS and
incubated for 1 h with the appropriate secondary antibodies (biotinylated goat anti-
rabbit or horse anti-goat, Vector Laboratories) diluted 1:400 in PBS containing
0.01% Triton X-100, rinsed in PBS and incubated with an avidin–biotin complex kit
(1:100; Vector Laboratories) for 1 h at RT. Sections were rinsed multiple times in
PBS, developed using a 3,3′-diaminobenzidine peroxidase kit (Vector Laboratories)
and further rinsed in PBS.
Sections immunolabeled for AT1, AT2 or TH were rinsed in PB, transferred to a
solution of 1% osmium tetroxide in PB for 1 h at RTand rinsed in PB before gradual
dehydration in 50–70% ethanol. They were then transferred to a contrast solution
containing 1% uranyl acetate in 70% ethanol for 1 h at RT, rinsed in 70% ethanol to
remove excess uranyl acetate and gradually dehydrated in 5 min baths of 70–100%
ethanol. Sections were cleared in propylene oxide and gradually infiltrated with Epon
resin by sequential immersion in a 2 : 1 mixture of propylene oxide and Epon resin
(30 min), 1:1 mixture of propylene oxide and Epon resin (1 h), 1:2 mixture of
propylene oxide and epon (1 h) and finally transferring the sections to Epon resin
overnight at 4 °C. The following day sections were transferred to freshly prepared
Epon resin for 1 h at RT, flat embedded and allowed to polymerize for a minimum of
72 h at 60 °C. After flat embedding was completed, the substantia nigra was clearly
identified using a bright-field microscope and re-dissected for ultramicrotomy.
Semi-thin (1 μm thick) and ultrathin (90 nm thick) sections were cut using a Leica EM
UC6 ultramicrotome (Leica Microsystems, Wetzlar, Germany). Ultrathin sections
were placed on copper grids and observed and photographed using a Hitachi
transmission electron microscopy (Hitachi, Tokyo, Japan) equipped with a
Hamamatsu Orca digital camera (Hamamatsu, Hamamatsu, Japan).
WB analysis. Whole homogenates and nuclear protein extracts from the nigral
region were processed for WB analysis. Equal amounts of protein were separated
by 5–10% Bis-Tris polyacrylamide gel, and transferred to nitrocellulose membranes.
Membranes were incubated overnight with primary antibodies against AT1 (1:200;
sc-31181), AT2 (1:200; sc-9040), NOX4 (1:2500; Abcam, Cambridge, England, UK,
ab133303), HDAC2 (1:200; sc-56685), α-tubulin (1:50 000; Sigma, T5168) or Na+/
K+-ATPase (1:200; sc-21712). The corresponding HRP-conjugated secondary
antibodies were used. Immunoreactivity was detected with an Immun-Star HRP
Chemiluminescent Kit (Millipore, Madrid, Spain) and imaged using a chemilumi-
nescence detection system (Molecular Imager ChemiDoc XRS System; Bio-Rad,
Hercules, CA, USA).
Specificity of antibodies. The specificity of the antibodies used for WB and
immunolabeling studies has been established in previous studies: AT1 sc-31181;59
AT2 sc-9040.60 In addition, the specificity of the antibodies was confirmed in our
laboratory by pre-adsorption with the corresponding synthetic peptide antigen. See
ref. 61 for details. We also used WB analysis of lysates from HEK293 cells
transfected with AT1 or AT2 tagged to fusion tail DDK (TA50011 from Origene,
Rockville, MD, USA; DDK tag: DYKDDDDK). Using HEK293 cells the specificity of
the antibodies was confirmed by the presence of a predominant immunoreactive
band in lysates from positively transfected cells and also by the absence of this
band in negative controls, which consisted of lysates of cells transfected with empty
vectors. See ref. 17 for details.
Transient transfection of AII receptors and rhodamine-
conjugated AII treatment of MES 23.5 dopaminergic cell line. To
study the cellular distribution of AII receptors, MES 23.5 cells were transiently
transfected with 1 μg AT1 (AT1/EGFP-N3) or 3 μg AT2 (AT2/YFP-N1) complimen-
tary DNA (cDNA) for 24 h using Lipofectamine LTX transfection reagent (Invitrogen,
Carlsbad, CA, USA). Twenty-four hours after transfection, cells were treated (60 min
and 24 h) with 100 nM AII, fixed in 4% paraformaldehyde, stained with Hoechst
(10 μg/ml) and observed using a confocal laser-scanning microscope (Leica SP5).
The effect of AII in the nuclear distribution of receptors was confirmed by WB
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analysis. For WB, MES 23.5 cells plated onto 350 mm plastic dishes were
transiently transfected with either cDNA (24 h) and then treated with 100 nM AII for
24 h. Nuclear proteins from control and treated cells (n= 4) were obtained using the
Nuclear Extract Kit (Active Motif, Carlsbad, CA, USA) and processed for WB
analysis using antibodies against GFP/YFP (1:800; Life Technologies, Waltham,
MA, USA; G10362) and HDAC2 (sc-56685; 1:800). Non-transfected cells were used
as a negative control for the GFP/YFP antibody.
For the study of the cellular distribution of AII, MES 23.5 cells were grown on glass
coverslips and treated with 0.5 nmol/ml rhodamine-conjugated AII (Phoenix
Pharmaceuticals, Burlingame, CA, USA). After 3 h cells were fixed in 4%
paraformaldehyde, stained with Hoechst (10 μg/ml) and observed by confocal
microscopy.
Isolation of fresh intact nuclei. Fresh intact nuclei were isolated and
purified from rat or mice brains and from the MES 23.5 cell line. Rats or mice were
killed by decapitation, and brains were quickly removed. All isolation procedures
were performed on ice or at 4 °C. Brains were rinsed with ice-cold isolation buffer A
containing 320 mM sucrose, 3 mM MgCl2 and 20 mM Tris, pH 7.4. Brain pieces or
MES 23.5 cells were homogenized in buffer A using a glass homogenizer.
Homogenates were centrifuged at 1000 × g for 15 min at 4 °C. Supernatants were
removed and pellets were resuspended in 4 ml buffer B (2.2 M sucrose, 1 mM
MgCl2 and 10 mM Tris, pH 7.4) and differentially centrifuged at 60 000 × g for 60 min
(Beckman XL-90 ultracentrifuge, Brea, CA, USA) using a swing out rotor at 4 °C.
After centrifugation, the pellet containing the isolated nuclei was resuspended and
washed by centrifugation in 2 ml buffer A. Protein content in isolated nuclei was
determined using the Pierce BCA Protein Assay Kit (Thermo Scientific, Fremont,
CA, USA). To confirm their integrity, fresh isolated nuclei were visualized without
fixation on a phase-contrast microscope immediately after isolation. Nuclei were
also stained on glass coverslips with the fluorescent nuclear marker Hoechst 33342
(10 μg/ml, Sigma), and examined using an inverted fluorescence microscope (Nikon
Eclipse TE300, Tokyo, Japan). For WB analysis, isolated nuclei were processed
using the Nuclear Extract Kit to remove DNA and conserve only the nuclear
proteins.
Effects of AII on in vitro transcription of mRNAs. The effects of AII on
mRNA transcription in isolated nuclei were studied using a standard in vitro RNA
transcription system (Promega, Madison, WI, USA). Freshly isolated nuclei (100 μg)
were first stimulated with 100 nM AII for 30 min at 37 °C. To determine the possible
mechanism involved in RNA transcription in response to AII stimulation, nuclei were
pre-treated with AII in the presence of the AT1 receptor antagonist losartan (3 μM),
the antioxidant NAC (0.5 mM), the NOX inhibitor DPI (5 μM) or the IP3 receptor
blocker 2-APB (50 μM). Pre-treated nuclei were then incubated with an in vitro RNA
transcription system consisting of 500 μM ATP, GTP and UTP; and 2 U/μl RNasin in
transcription buffer (Promega) at 37 °C for 1 h. After incubation, RNA was extracted
using Trizol (Invitrogen) according to the manufacturer’s instructions. The
concentration of RNA was estimated using a Nanoquant plate and an Infinite
M200 multiwell plate reader (Tecan, Infinite M200, Salzburg, Austria). Total RNA
(1 μg) was reverse-transcribed to cDNA with deoxynucleotide triphosphate, random
primers and Moloney murine leukemia virus reverse transcriptase (200 U;
Invitrogen). Real-time PCR was performed to evaluate the relative levels of mRNA
for several genes. Experiments were performed using a real-time iCycler PCR
platform (Bio-Rad). GAPDH and β-actin were used as housekeeping genes and
were amplified in parallel with the genes of interest. Data were evaluated by the
delta–delta Ct method (2−ΔΔCt), where Ct is the cycle threshold. The expression
of each gene was obtained as relative to the housekeeping transcripts. Forward (F)
and reverse (R) primers were designed for each gene using C software (PREMIER
Biosoft, Palo Alto, CA, USA) (Supplementary Table S1).
Measurement of intranuclear ROS, calcium and NO levels. To
study the role of AII receptors in nuclear ROS generation, isolated nuclei from MES
23.5 cells and rat or mice brains were assayed for ROS production using the
fluorescent dye dihydroethidium (DHE; Sigma). In the presence of ROS DHE is
oxidized to ethidium, which binds to DNA and stains nuclei with bright red
fluorescence. Isolated nuclei (15 μg) were treated with 100 nM AII alone or
combined with the receptor antagonists losartan (3 μM) or PD123319 (1 μM), the
antioxidant NAC (0.5 mM) or the NOX inhibitor DPI (5 μM). The fluorescent dye
DHE was added to the nuclei at a final concentration of 0.1 mM in a fresh working
solution containing 1 mM NADPH, 3 mM MgCl2, 20 mM Tris and 320 mM sucrose,
pH 7.40. Fluorescence was measured for 1 h at 37 °C (excitation/emission
wavelength= 535 nm/610 nm) using a fluorescent plate reader (Tecan,
Infinite M200).
Calcium levels were estimated in isolated nuclei using the ratiometric calcium
indicator Fura-2/AM (Molecular Probes). After isolation, brain nuclei were
resuspended in 0.5 ml buffer containing 25 mM HEPES, 100 mM KCl, 2 mM
K2HPO4 and 4 mM MgCl2. Fura-2/AM (5 μM) was added to the nuclear suspension
and incubated for 45 min at 37 °C. Nuclei were washed twice by centrifugation at
2500 × g for 5 min at RT to remove non-incorporated Fura-2/AM and resuspended in
buffer containing 800 nM CaCl2. Calcium levels were estimated after treatment with
100 nM AII or AII+losartan (3 μM) in a spectrofluorimeter (Perkin-Elmer, Norwalk, CT,
USA). Fluorescence emission was detected at 509 nm and was expressed as the
ratio of the two excitation wavelengths (340/380). Ca+2 concentrations were estimated
by calibrating the fluorescent signal by sequential addition of 0.01% Triton and 1 mM
CaCl2 and 4 mM EGTA to obtain the minimum fluorescence ratio. Data were
normalized to the values of the control group (100%) to counteract possible variability
among assays.
Nuclear NO production was estimated using the fluorescent dye 4-amino-5-
methylamino-2′,7′-difluorofluorescein diacetate (DAF, Sigma). Isolated nuclei from rat
brain were pre-incubated with 10 μM DAF in buffer containing 140 mM NaCl, 14 mM
glucose, 4.7 mM KCl, 2.5 mM CaCl2, 1.8 mM MgSO4, 1.8 mM KH2PO4 and 100 μM
L-arginine, pH 7.4 for 30 min at 37 °C. Nuclei were washed to remove any unbound
dye and then incubated with 100 nM AII in the presence of losartan (3 μM),
PD123,319 (1 μM), the NOS inhibitor L-NAME (50 μM, Sigma) or buffer alone. DAF
fluorescence was measured using an Infinite M200 multiwell plate reader (Tecan) at
488 and 510 nm wavelengths (excitation and emission, respectively). NO values were
expressed as percentage of the corresponding controls.
Statistical analysis. All data were obtained from at least three independent
experiments and were expressed as mean values± S.E.M. Two-group comparisons
were analyzed using Student’s t-test while multiple comparisons were analyzed
using one-way ANOVA followed by post hoc Holm–Sidak test. Normality of
populations and homogeneity of variances were tested before each ANOVA.
Differences were considered significant at Po0.05. Statistical analyses were
carried out with SigmaStat 3.0 (Jandel Scientific; San Rafael, CA, USA).
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